Related Experiment Video
Updated: May 11, 2026
15:17
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
14.3K
H2AC14 is a novel and reliable prognostic marker for CRC
Min Luo1,2, Yue Zhang1, Pei-Feng Li1
1Institute for Translational Medicine, Qingdao University, Qingdao, China.
Medicine
|January 10, 2026
Summary
Histone Cluster 2 H2A Family Member C14 (H2AC14) is overexpressed in colorectal cancer (CRC) and promotes tumor metastasis. This suggests H2AC14 may serve as a diagnostic biomarker for CRC, aiding in treatment and prognosis.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Colorectal cancer (CRC) incidence and mortality are rising, necessitating new biomarkers for prognosis and treatment.
- Histone Cluster 2 H2A Family Member C14 (H2AC14) is a histone protein with an unexplored role in CRC.
Purpose of the Study:
- To investigate the potential role of H2AC14 in colorectal cancer (CRC) progression, diagnosis, and prognosis.
- To explore H2AC14 as a potential diagnostic biomarker for CRC.
Main Methods:
- Bioinformatics analysis using The Cancer Genome Atlas-Colon Adenocarcinoma database.
- Gene expression analysis in CRC cell lines (LOVO, HT29, HCT116, SW480) and normal colon cells (NCM460).
- Gene silencing experiments to assess the functional role of H2AC14 in cell migration and epithelial-mesenchymal transition (EMT).
Main Results:
- H2AC14 is significantly overexpressed in CRC tissues compared to normal tissues.
- H2AC14 expression correlates with TNM staging, prognosis, and overall survival in CRC patients.
- Silencing H2AC14 reduced CRC cell migration and downregulated EMT-associated genes, indicating H2AC14 promotes metastasis.
- Area under curve analysis confirmed H2AC14's diagnostic predictive value for CRC.
Conclusions:
- H2AC14 is upregulated in colorectal cancer and promotes tumor metastasis by facilitating the epithelial-mesenchymal transition process.
- H2AC14 demonstrates potential as a diagnostic biomarker for CRC.
- Further clinical research is warranted to explore H2AC14's therapeutic and prognostic implications in CRC.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...